title: Origin of the vasculature supporting growth of primary patient tumor xenografts.
abstract: BACKGROUND
  Studies of primary patient tumor xenografts grown in immunodeficient mice have shown that these tumors histologically and genetically closely resemble the original tumors. These patient xenograft models are becoming widely used for therapeutic efficacy studies. Because many therapies are directed at tumor stromal components and because the tumor microenvironment also is known to influence the response of a tumor to therapy, it is important to understand the nature of the stroma and, in particular, the vascular supply of patient xenografts.
  
  
  METHODS
  Patient tumor xenografts were established by implanting undisrupted pieces of patient tumors in SCID mice. For this study, formalin fixed, paraffin embedded specimens from several types of solid tumors were selected and, using species-specific antibodies which react with formalin fixed antigens, we analyzed the species origin of the stroma and blood vessels that supported tumor growth in these models. Additionally, we investigated the kinetics of the vascularization process in a colon tumor and a mesothelioma xenograft. In mice bearing a head and neck xenograft, a perfusion study was performed to compare the functionality of the human and mouse tumor vessels.
  
  
  RESULTS
  In patient tumors which successfully engrafted, the human stroma and vessels which were engrafted as part of the original tumor did not survive and were no longer detectable at the time of first passage (15-25 weeks). Uniformly, the stroma and vessels supporting the growth of these tumors were of murine origin. The results of the kinetic studies showed that the loss of the human vessels and vascularization by host vessels occurred more rapidly in a colon tumor (by 3 weeks) than in a mesothelioma (by 9 weeks). Finally, the perfusion studies revealed that while mouse vessels in the periphery of the tumor were perfused, those in the central regions were rarely perfused. No vessels of human origin were detected in this model.
  
  
  CONCLUSIONS
  In the tumors we investigated, we found no evidence that the human stromal cells and vessels contained in the original implant either survived or contributed in any substantive way to the growth of these xenografts.
authors: Department of Immunology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. Bonnie.Hylander@roswellpark.org
authors: Bonnie L
authors: BL
authors: Hylander
authors: Natalie
authors: N
authors: Punt
authors: Haikuo
authors: H
authors: Tang
authors: Joanna
authors: J
authors: Hillman
authors: Mary
authors: M
authors: Vaughan
authors: Wiam
authors: W
authors: Bshara
authors: Rose
authors: R
authors: Pitoniak
authors: Elizabeth A
authors: EA
authors: Repasky
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D003110:Colonic Neoplasms / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000473:pathology; D051379:Mice; D016513:Mice, SCID; D008875:Middle Aged; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000473:pathology* / Q000628:therapy; D009389:Neovascularization, Pathologic / Q000473:pathology* / Q000628:therapy; D014407:Tumor Cells, Cultured; D059016:Tumor Microenvironment
references: Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9345-9
references: 1924398
references: Cancer Res. 2004 Mar 1;64(5):1712-21
references: 14996731
references: Cancer Res. 2002 Oct 15;62(20):5800-6
references: 12384541
references: J Transl Med. 2005 May 19;3(1):22
references: 15943879
references: Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14608-13
references: 11121063
references: Clin Pharmacol Ther. 2009 Feb;85(2):217-21
references: 19005462
references: Gynecol Oncol. 1999 Feb;72(2):161-70
references: 10021295
references: PLoS One. 2012;7(3):e33571
references: 22442699
references: J Transl Med. 2012 Jun 18;10:125
references: 22709571
references: Am J Pathol. 1993 Aug;143(2):528-37
references: 8342600
references: PLoS One. 2012;7(6):e38422
references: 22675560
references: Eur J Cardiothorac Surg. 2009 Sep;36(3):454-9
references: 19502076
references: Cancer Res. 2001 Nov 1;61(21):7846-54
references: 11691802
references: PLoS One. 2012;7(1):e29623
references: 22303438
references: Nat Protoc. 2009;4(11):1670-80
references: 19876027
references: Mol Cancer Ther. 2003 Aug;2(8):729-37
references: 12939462
references: Int J Microcirc Clin Exp. 1997 May-Jun;17(3):138-42
references: 9272464
references: Clin Cancer Res. 2008 Oct 15;14(20):6456-68
references: 18927285
references: J Pathol. 2011 Oct;225(2):212-21
references: 21710693
references: Biotechniques. 2010 Mar;48(3):211-8
references: 20359302
references: Am J Pathol. 2000 Feb;156(2):361-81
references: 10666364
references: Nat Rev Clin Oncol. 2012 Apr 17;9(6):338-50
references: 22508028
references: Cancer Biol Ther. 2009 Dec;8(23):2275-83
references: 19829072
references: Lab Invest. 2009 Jan;89(1):91-7
references: 19002108
references: Transplantation. 1987 Jun;43(6):896-903
references: 3296356
references: Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4274-80
references: 21262804
references: J Clin Invest. 1995 Oct;96(4):1815-22
references: 7560073
references: Clin Cancer Res. 2006 Aug 1;12(15):4652-61
references: 16899615
references: Clin Exp Metastasis. 2000;18(3):231-7
references: 11315096
references: Clin Cancer Res. 2012 Oct 1;18(19):5314-28
references: 22825584
references: Cancer Res. 2006 Apr 1;66(7):3351-4, discussion 3354
references: 16585151
references: Mol Cancer Ther. 2011 Aug;10(8):1311-6
references: 21673092